论文部分内容阅读
目的:探讨曲美他嗪治疗缺血性心肌病心力衰竭疗效观察。方法:选取该院心内科2014年7月至2015年9月共收治40例缺血性心肌病心力衰竭患者为研究对象,将患者分为对照组和观察组,对照组患者采取常规治疗,观察组患者在对照组常规治疗上给予曲美他嗪治疗措施,对比两组前后治疗总有效率。结果:观察组患者治疗总有效率为(96%)明显优于对照组患者治疗总有效率(88%);两组患者不良反应发生率在比较后差异大,具有统计学的意义(P<0.05)。结论:将曲美他嗪纳入缺血性心肌病心力衰竭临床治疗中,提高了患者对知识的掌握程度与降低了患者对于疾病的心理压力,值得临床大力推广。
Objective: To investigate the curative effect of trimetazidine on heart failure of ischemic cardiomyopathy. Methods: Forty patients with heart failure of ischemic cardiomyopathy were enrolled in this hospital from July 2014 to September 2015. The patients were divided into control group and observation group. Patients in control group were treated routinely and observed The patients in the control group were treated with trimetazidine in routine therapy, and the total effective rate was compared between the two groups before and after treatment. Results: The total effective rate (96%) in the observation group was significantly better than that in the control group (88%). The incidence of adverse reactions in the two groups was significantly different after the comparison, with statistical significance (P < 0.05). Conclusion: Trimetazidine into the clinical treatment of ischemic cardiomyopathy heart failure, improve the patient’s mastery of knowledge and reduce the patient’s psychological stress on the disease, it is worth promoting clinical efforts.